Taylor R. Brooks

Taylor R. Brooks

Hematology Oncology
10201 Carnegie Avenue
Cleveland, OH 44106

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 26 publications

Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton's tyrosine kinase inhibitor therapy.

Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton's tyrosine kinase inhibitor therapy.

Journal: Blood cancer journal
Published: December 12, 2025

Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma.

Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma.

Journal: Blood advances
Published: September 24, 2025

Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma.

Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma.

Journal: Blood advances
Published: September 24, 2025

Benefit of Rituximab Maintenance After First-line Bendamustine-Rituximab in Patients with Mantle Cell Lymphoma.

Benefit of Rituximab Maintenance After First-line Bendamustine-Rituximab in Patients with Mantle Cell Lymphoma.

Journal: Blood advances
Published: September 24, 2025

Prognostic impact of TP53 alterations in cases of newly diagnosed large B-cell lymphoma.

Prognostic impact of TP53 alterations in cases of newly diagnosed large B-cell lymphoma.

Journal: Leukemia
Published: September 02, 2025

Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma after frontline DA-EPOCH-R.

Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma after frontline DA-EPOCH-R.

Journal: Haematologica
Published: May 23, 2025

Carfilzomib in combination with R-CHOP for initial treatment of patients with non-germinal center diffuse large B-cell lymphoma: a multicenter, single arm, phase 1/2 study.

Carfilzomib in combination with R-CHOP for initial treatment of patients with non-germinal center diffuse large B-cell lymphoma: a multicenter, single arm, phase 1/2 study.

Journal: Leukemia & lymphoma
Published: May 21, 2025

Web Exclusive. Annals Guide to Journal Club - Time-Restricted Eating Without Calorie Counting for Weight Loss in a Racially Diverse Population.

Web Exclusive. Annals Guide to Journal Club - Time-Restricted Eating Without Calorie Counting for Weight Loss in a Racially Diverse Population.

Journal: Annals of internal medicine
Published: March 25, 2025

Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab.

Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab.

Journal: Blood
Published: March 06, 2025

Treatment and outcomes of progression of disease post-CAR T-cell therapy in mantle cell lymphoma: a multicenter analysis.

Treatment and outcomes of progression of disease post-CAR T-cell therapy in mantle cell lymphoma: a multicenter analysis.

Journal: Blood advances
Published: February 25, 2025

Peer Review: Insights Gleaned From Observing the Editorial Process at Annals of Internal Medicine.

Peer Review: Insights Gleaned From Observing the Editorial Process at Annals of Internal Medicine.

Journal: Annals of internal medicine
Published: November 18, 2024

The CNS relapse in T-cell lymphoma index predicts CNS relapse in patients with T- and NK-cell lymphomas.

The CNS relapse in T-cell lymphoma index predicts CNS relapse in patients with T- and NK-cell lymphomas.

Journal: Blood advances
Published: January 29, 2024
Showing 1-12 of 26

Last Updated: 09/26/2026